Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155
International Journal of Medical Sciences · 28.10.2024 · 21 (14) · 2781-2798
DOI: 10.7150/ijms.102123 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Medical Sciences, erschienen am 28.10.2024. Verfasst von Hongbo Qian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: MicroRNAs, Neoplasms. Die Arbeit wurde bisher 70-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
MicroRNAs (miRNAs)-based therapies hold great promise for cancer treatment, challenges such as expression variability, off-target effects, and limited clinical effectiveness have led to the withdrawal of many clinical trials. This review investigates the setbacks in miRNA-based therapies by examining miR-21, miR-34, and miR-155, highlighting their functional complexity, off-target effects, and the challenges in delivering these therapies effectively. Moreover, It highlights recent advances in delivery methods, combination therapies, and personalized treatment approaches to overcome these challenges. This review highlights the intricate molecular networks involving miRNAs, particularly their interactions with other non-coding RNAs, such as long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), emphasizing the pivotal role of miRNAs in cancer biology and therapeutic strategies. By addressing these hurdles, this review aims to steer future research toward harnessing the potential of miRNA therapies to target cancer pathways effectively, enhance anti-tumor responses, and ultimately improve patient outcomes in precision cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
- Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, Sichuan, China.
- Department of Biochemistry, Faculty of Medicine, Medical University of Warsaw, Warsaw 02-091, Poland.
- Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Zitieren
APA
Qian, H., Maghsoudloo, M., Kaboli, P. J., Babaeizad, A., Cui, Y., Fu, J., Wang, Q., & Imani, S. (2024). Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155. International Journal of Medical Sciences, 21(14), 2781-2798. https://doi.org/10.7150/ijms.102123
Vancouver
Qian H, Maghsoudloo M, Kaboli PJ, Babaeizad A, Cui Y, Fu J, et al. Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155. International Journal of Medical Sciences. 2024;21(14):2781-2798. doi:10.7150/ijms.102123
BibTeX
@article{Qian2024,
author = {Qian, Hongbo and Maghsoudloo, Mazaher and Kaboli, Parham Jabbarzadeh and Babaeizad, Ali and Cui, Yulan and Fu, Junjiang and Wang, Qingjing and Imani, Saber},
title = {Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155},
journal = {International Journal of Medical Sciences},
year = {2024},
volume = {21},
number = {14},
pages = {2781--2798},
doi = {10.7150/ijms.102123}
}
EUVIMED